Cirrhosis, Liver Clinical Trial
Official title:
Longitudinal Monitoring of Stool Characteristics
NCT number | NCT05604274 |
Other study ID # | BAJAJ033 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | October 28, 2022 |
Est. completion date | October 28, 2023 |
Verified date | October 2022 |
Source | Hunter Holmes Mcguire Veteran Affairs Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In patients with cirrhosis and healthy controls to determine the utility of an App to classify BSS compared to assessment made by the patients themselves using the BSS and correlate these with other stool characteristics and gut microbiota.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | October 28, 2023 |
Est. primary completion date | October 28, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - For cirrhosis subjects must meet all of the following inclusion criteria to be eligible: 1. Male and female subjects aged = 18 years. 2. Cirrhosis 3. Able and willing to voluntarily complete the informed consent process 4. Familiar with smartphone technology 5. Available for and agree to all study procedures, including taking the pictures of the stool and collection of stool For controls : 1. Male and female subjects aged = 18 years. 2. Absence of chronic diseases requiring prescription medications 3. Able and willing to voluntarily complete the informed consent process 4. Familiar with smartphone technology 5. Available for and agree to all study procedures, including taking the pictures of the stool and collection of stool for microbiome analysis Exclusion Criteria: Subjects with cirrhosis meeting any of the following criteria are not eligible for study enrollment: 1. Unclear diagnosis of cirrhosis 2. History of liver transplant 3. For those on lactulose, they need to be on it for at least 2 weeks 4. Unfamiliar with smartphones 5. Apart from chronic liver disease, any acute or chronic medical, surgical, psychiatric, or social condition including history of cerebrovascular disease (stroke, transient ischemic attack) or dementia, that may increase the subject risk associated with study participation, compromise adherence to study procedures and requirements, confound interpretation of the results, and, in the judgment of the investigator, make the subject inappropriate for enrollment. For healthy controls 1. Any chronic disease requiring prescription medications 2. Unfamiliar with smartphones |
Country | Name | City | State |
---|---|---|---|
United States | Hunter Holmes McGuire VA Medical Center | Richmond | Virginia |
Lead Sponsor | Collaborator |
---|---|
Hunter Holmes Mcguire Veteran Affairs Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | App use comfort measured by survey | A survey designed to assess acceptability of this App at baseline and at 2 weeks; higher score=good | 2 weeks | |
Secondary | Quality of life using Sickness Impact Profile | we will test association of the stool characteristics with quality of life; higher=good | 2 weeks | |
Secondary | Cognitive testing using PHES | we will test association of the stool characteristics with PHES values; higher=good | 2 weeks | |
Secondary | Alpha diversity using Shannon index of microbiome | we will test association of the stool characteristics with microbial characteristics | 2 weeks | |
Secondary | Bristol stool scale by subjects | we will test association of the stool characteristics gauged through the App versus the Bristol stool scale by subjects | 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05793983 -
S100A8/A9 and Innate Immunity in Liver Disease
|
||
Completed |
NCT04604860 -
Use of EL-FIT App to Promote Physical Activity
|
N/A | |
Recruiting |
NCT05928624 -
A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients
|
N/A | |
Active, not recruiting |
NCT01438970 -
Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function
|
Phase 2 | |
Recruiting |
NCT05998330 -
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
|
N/A | |
Completed |
NCT04581369 -
Cirrhosis Medical Home
|
N/A | |
Withdrawn |
NCT04244877 -
Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
|
Phase 3 | |
Recruiting |
NCT04588077 -
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
|
Phase 4 | |
Recruiting |
NCT05538962 -
Longitudinal Monitoring of Inflammation in Cirrhosis
|
N/A | |
Completed |
NCT04082780 -
Rifamycin in Minimal Hepatic Encephalopathy
|
Phase 2 | |
Completed |
NCT03850977 -
Is There an Association Between Chronic Pancreatitis and Pulmonary Function
|
||
Active, not recruiting |
NCT03736265 -
Carvedilol for Prevention of Esophageal Varices Progression
|
N/A | |
Recruiting |
NCT04530760 -
Intraabdominal Hypertension and Occurrence of Microaspiration in Cirrhotics Under Mechanical Ventilation
|
||
Recruiting |
NCT05093218 -
Effect of Branch Chain Amino Acid Therapy on Sarcopenia in Children With Chronic Liver Disease.
|
N/A | |
Recruiting |
NCT03437876 -
Study on Effect of Intestinal Microbiota Transplantation in Hepatitis B Virus Induced Cirrhosis
|
N/A | |
Recruiting |
NCT04867954 -
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
|
||
Completed |
NCT04643795 -
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02344680 -
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
|
||
Completed |
NCT04121520 -
Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey
|
||
Not yet recruiting |
NCT04591522 -
Fecal Microbiota Transplantation in Cirrhosis
|
N/A |